Featuring

Professor John McMurray, Professor of Cardiology (Cardiology & Metabolic Health), School of Cardiovascular and Metabolic Health
Professor Richard Hobbs, Mercian Professor of Primary Care, University of Oxford

References

1. Piccirillo F, Liporace P, Nusca A et al. Effects of finerenone on cardiovascular and chronic kidney diseases: a new weapon against cardiorenal morbidity and mortality‑a comprehensive review. J Cardiovasc Dev Dis 2023;10:236.
2. Kolkhof P, Jaisser F, Kim S-Y et al. Steroidal and novel non‑steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. In Bauersachs J et al (eds): Heart failure. Springer International Publishing, Cham, Switzerland, 2017:271–305.
3. Spironolactone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/12015/smpc#gref.
4. Eplerenone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8810/smpc.

1. Bennani SY et al. Int J Cardiovasc Imaging 2016;32:1403–13

Professor Marianna Fontana, Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, University College London

For more expert-led non-promotional content on heart failure, cardiac amyloidosis and ATTR-CM, please visit the Pfizer Medical website. Clicking this link will redirect you to the Pfizer Medical website, a non-promotional website developed and funded by Pfizer Ltd. for UK healthcare professionals.

Abbreviation:
ATTR-CM: Transthyretin amyloid cardiomyopathy.

PP-UNP-GBR-14079 | March 2026

Dr William E Moody, Consultant Cardiologist, Queen Elizabeth Hospital, Birmingham

For more expert-led non-promotional content on heart failure, cardiac amyloidosis and transthyretin amyloid cardiomyopathy, please visit the Pfizer Medical website. Clicking this link will redirect you to the Pfizer Medical website, a non-promotional website developed and funded by Pfizer Ltd. for UK healthcare professionals.

Reference

Moody, William E et al. “British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis.” Echo research and practice vol. 10,1 13. 31 Aug. 2023, doi:10.1186/s44156-023-00028-7

Abbreviations:
ECHO: echocardiography; TTE: transthoracic echocardiography.

PP-UNP-GBR-14075 | March 2026

References

1. Mebazaa A et al. Lancet 2022;400:1938–52

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370.